1147 related articles for article (PubMed ID: 11908558)
1. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
2. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
3. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
Laine L
Rev Gastroenterol Disord; 2004; 4 Suppl 4():S33-41. PubMed ID: 15580145
[TBL] [Abstract][Full Text] [Related]
5. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
Laine L
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
[TBL] [Abstract][Full Text] [Related]
6. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
Targownik LE; Metge CJ; Leung S; Chateau DG
Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
8. Inadequate prevention of NSAID-induced gastrointestinal events.
Herings RM; Goettsch WG
Ann Pharmacother; 2004 May; 38(5):760-3. PubMed ID: 15031416
[TBL] [Abstract][Full Text] [Related]
9. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants.
Lanas A; García-Rodríguez LA; Arroyo MT; Bujanda L; Gomollón F; Forné M; Aleman S; Nicolas D; Feu F; González-Pérez A; Borda A; Castro M; Poveda MJ; Arenas J;
Am J Gastroenterol; 2007 Mar; 102(3):507-15. PubMed ID: 17338735
[TBL] [Abstract][Full Text] [Related]
10. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
[TBL] [Abstract][Full Text] [Related]
11. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
[TBL] [Abstract][Full Text] [Related]
12. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials.
Rostom A; Wells G; Tugwell P; Welch V; Dubé C; McGowan J
J Rheumatol; 2000 Sep; 27(9):2203-14. PubMed ID: 10990235
[TBL] [Abstract][Full Text] [Related]
13. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
Chan FK; Graham DY
Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
[TBL] [Abstract][Full Text] [Related]
14. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.
Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F
Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111
[TBL] [Abstract][Full Text] [Related]
15. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
Battistella M; Mamdami MM; Juurlink DN; Rabeneck L; Laupacis A
Arch Intern Med; 2005 Jan; 165(2):189-92. PubMed ID: 15668365
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Wolfe F; Zhao S; Pettitt D
J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
[TBL] [Abstract][Full Text] [Related]
17. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
18. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin.
Cheetham TC; Levy G; Niu F; Bixler F
Ann Pharmacother; 2009 Nov; 43(11):1765-73. PubMed ID: 19809010
[TBL] [Abstract][Full Text] [Related]
20. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage.
van Soest EM; Sturkenboom MC; Dieleman JP; Verhamme KM; Siersema PD; Kuipers EJ
Aliment Pharmacol Ther; 2007 Jul; 26(2):265-75. PubMed ID: 17593072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]